R&D | December 22, 2025
Xeureka & UBE launch joint cancer drug discovery program
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
The company also reported significant progress toward its internally defined Sustainable Development Goals
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Subscribe To Our Newsletter & Stay Updated
